<DOC>
	<DOCNO>NCT03042013</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety tolerability continuous treatment ASP8273 subject participate Astellas-sponsored ASP8273 study complete , minimum , primary analysis complete individual study evaluation period investigator feel subject may potential continue derive clinical benefit treatment ASP8273 .</brief_summary>
	<brief_title>A Study Subjects Who Are Participating Astellas-sponsored ASP8273 Study</brief_title>
	<detailed_description>This multicenter , rollover study subject non-small cell lung cancer ( NSCLC ) epidermal growth factor receptor ( EGFR ) activate mutation currently participate study evaluate ASP8273 . Subjects sign inform consent cycle 1 day 1 visit . The assessment last treatment visit parent study utilized cycle 1 day 1 visit . Either local central laboratory may utilize cycle 1 day 1 visit assessment use last treatment visit parent study . The subject receive ASP8273 study drug rollover study return ASP8273 study drug parent study . Subjects continue subsequent 28-day cycle 1 discontinuation criterion meet . Upon enrollment , subject few 6 cycle study drug dose parent study return clinic day 1 cycle cycle 5 . After cycle 5 , subject switch day 1 every odd cycle clinic visit . Subjects 6 cycle study drug dose upon enrollment rollover study return clinic day 1 every odd cycle ( e.g. , cycle 3 , 5 , etc. ) . Imaging method frequency perform per standard care . An end treatment study visit conduct 30 day last dose study medication .</detailed_description>
	<criteria>Subject must participate Astellassponsored ASP8273 study complete , minimum , primary analysis complete individual study evaluation period requirement . Subject must meet discontinuation criterion parent study . Subject must receive stable dose ASP8273 14 day minimum able enroll rollover study without treatment interruption study drug , 21 consecutive day treatment interruption study drug within parent study . Subject derive clinical benefit without persistent intolerable toxicity continue treatment ASP8273 . Subject agree participate another interventional study treatment . Subject develop persistent intolerable toxicity ASP8273 treatment parent study . Subject receive systemic anticancer treatment parent study entry ( radiation local area bone brain receive parent ASP8273 study permit ) . Subject require follow medication exclude : Chemotherapy , radiotherapy , immunotherapy medication intend antitumor activity Investigational product therapy ASP8273 Strong inhibitor inducer CYP3A4 Permeabilityglycoprotein ( Pgp ) substrates narrow therapeutic index Subject condition may require treatment study may make subject unsuitable study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ASP8273</keyword>
	<keyword>Non-Small-Cell Lung Cancer</keyword>
	<keyword>EGFR mutation</keyword>
	<keyword>Oncology</keyword>
</DOC>